Scholarlink

Background <p>The relationship between smoking and blood viscosity is well established. However, the role of blood viscosity in the development of chronic obstructive pulmonary disease (COPD) and its impact on lung function decline remains unclear. Therefore, we aimed to investigate the association of blood viscosity with COPD and lung function decline, independent of smoking status.</p> Methods <p>Data from 292 participants in the Korea COPD Subgroup Study (KOCOSS), a multicenter prospective cohort, were analyzed. Subjects were classified into four groups based on smoking history and COPD status. Multiple linear regression analysis was performed to determine the association between baseline viscosity and lung function decline after adjusting for age, sex, smoking status, and COPD status.</p> Results <p>Of the 292 participants, 93 (31.8%) patients had COPD. Ever smokers with or without COPD were older than never smokers and predominantly male. Never smokers with COPD reported the highest scores for the Modified Medical Research Council Dyspnea Scale. Blood viscosity was significantly higher in ever smokers (with COPD: 9.0 ± 1.4; without COPD 9.2 ± 1.5) than in never smokers (with COPD: 8.7 ± 1.8; without COPD: 8.4 ± 1.5). Viscosity did not differ significantly with the presence of COPD within the same smoking category. Adjusted multiple linear regression revealed that baseline blood viscosity was not associated with 2-year declines in forced expiratory volume in 1&#xa0;s (<i>p</i> = 0.557), forced vital capacity (<i>p</i> = 0.686), or diffusing capacity of the lung for carbon monoxide (<i>p</i> = 0.947).</p> Conclusion <p>Blood viscosity appeared to be more closely associated with smoking-related hemorheological changes than with COPD. Its potential as a predictive biomarker for lung function decline appears to be limited, necessitating further long-term investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Blood viscosity is associated with smoking status rather than the presence of chronic obstructive pulmonary disease: findings from the Korea COPD Subgroup Study (KOCOSS)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月4日

查看全文
  • Ye Jin Lee,
  • Hye-Rin Kang,
  • Sang Hyuk Kim,
  • Hyun Jung Kim,
  • Jae Seung Lee,
  • Chang-Hoon Lee,
  • Sung Kyoung Kim,
  • Yu-Il Kim,
  • Kwang Ha Yoo,
  • Youlim Kim

摘要

Background

The relationship between smoking and blood viscosity is well established. However, the role of blood viscosity in the development of chronic obstructive pulmonary disease (COPD) and its impact on lung function decline remains unclear. Therefore, we aimed to investigate the association of blood viscosity with COPD and lung function decline, independent of smoking status.

Methods

Data from 292 participants in the Korea COPD Subgroup Study (KOCOSS), a multicenter prospective cohort, were analyzed. Subjects were classified into four groups based on smoking history and COPD status. Multiple linear regression analysis was performed to determine the association between baseline viscosity and lung function decline after adjusting for age, sex, smoking status, and COPD status.

Results

Of the 292 participants, 93 (31.8%) patients had COPD. Ever smokers with or without COPD were older than never smokers and predominantly male. Never smokers with COPD reported the highest scores for the Modified Medical Research Council Dyspnea Scale. Blood viscosity was significantly higher in ever smokers (with COPD: 9.0 ± 1.4; without COPD 9.2 ± 1.5) than in never smokers (with COPD: 8.7 ± 1.8; without COPD: 8.4 ± 1.5). Viscosity did not differ significantly with the presence of COPD within the same smoking category. Adjusted multiple linear regression revealed that baseline blood viscosity was not associated with 2-year declines in forced expiratory volume in 1 s (p = 0.557), forced vital capacity (p = 0.686), or diffusing capacity of the lung for carbon monoxide (p = 0.947).

Conclusion

Blood viscosity appeared to be more closely associated with smoking-related hemorheological changes than with COPD. Its potential as a predictive biomarker for lung function decline appears to be limited, necessitating further long-term investigation.